News 2021 Archives - Cognition Therapeutics, Inc.

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering

PURCHASE, N.Y., Nov. 15, 2021 — Cognition Therapeutics, Inc. [Nasdaq: CGTX], a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced the closing of an additional 565,217 shares of its common …

Cognition Therapeutics Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in connection with Initial Public Offering Read More »

Cognition Therapeutics Adds Public Company Financial and Operational Expertise to Board of Directors with Appointment of Ellen B. Richstone

Cognition Therapeutics appointed Ellen B. Richstone to the company’s board of directors, where she will serve as the chair of the audit committee. Mrs. Richstone brings extensive financial and operational experience to Cognition’s board.

Cognition Therapeutics Announces Pricing of Upsized Initial Public Offering

Cognition Therapeutics today announced the pricing of its upsized initial public offering of 3,768,116 shares of its common stock at a public offering price of $12.00 per share.

Cognition Therapeutics Announces Launch of its Initial Public Offering

Purchase, NY, Oct. 04, 2021 — Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina (the “Company” or “Cognition”), today announced that it has launched an initial public offering of 3,350,000 shares of …

Cognition Therapeutics Announces Launch of its Initial Public Offering Read More »

Cognition Therapeutics Announces Election of Jack Khattar Chairman of the Board

Cognition’s CEO, Lisa Ricciardi and CFO, James O’Brien plan to make a company presentation at the annual H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

Cognition Therapeutics to Present Corporate and Clinical Update at H.C. Wainwright Global Life Sciences Conference

Cognition’s CEO, Lisa Ricciardi and CFO, James O’Brien plan to make a company presentation at the annual H.C. Wainwright Global Life Sciences Conference, being held virtually March 9-10, 2021.

Cognition Therapeutics Publishes Biomarker Findings from Clinical Study of CT1812 Supporting Positive Impact on Synapse Biology

Cognition publishes evidence that treatment with CT1812 improves disease-related biology in patients with Alzheimer’s disease in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.

Cognition Therapeutics Publishes Evidence Identifying Receptor Integral in Parkinson’s Disease Pathology

Cognition publishes findings identifying sigma-2 (σ-2) receptor as integral in Parkinson’s disease pathology

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance

Pittsburgh, January 5, 2021 – Cognition Therapeutics, Inc., a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that President and CEO Lisa Ricciardi is participating in the Biotech Showcase™ 2021 conference and providing an on-demand company presentation. In addition, Ms. Ricciardi will be participating in …

Cognition Therapeutics Reviews 2020 Accomplishments and Provides 2021 Guidance Read More »